-
-
Metabolic syndrome (ms) is an accepted risk factor for adverse coronary events as well as mortality. It has been associated with accelerated coronary atherosclerosis, which is typically subclinical.
-
-
It has long been taught that lipid levels measured during hospitalization for an acute illness will be artificially low because of an acute-phase metabolic reaction. Consequently, many physicians wait weeks after hospitalization to measure lipids when they have returned to baseline levels and then start appropriate lipid lowering therapy.
-
Sirolimus — and paclitaxel-eluting stents have been available for use in the United States since 2003 and have a well-known safety and efficacy profile. However, these drug and polymer combinations are applied to older generation stents, which are less deliverable than the newer generation stents.
-
The introduction of hybrid pet/ct scanners has raised the issue of the benefits of adding CT coronary calcification measurements to stress testing in intermediate risk patients.
-
Inappropriate shocks from implantable cardioverter defibrillators (ICDs) continue to be a major problem. In this study, the MADIT II investigators review the experience in that study with inappropriate shocks in a primary prevention, post-myocardial infarction cohort.
-
In this paper, jones and colleagues from the Brigham and Women's Hospital in Boston report a seven-year experience with transvenous extraction of pacemakers and ICD leads.
-
Pioglitazone and heart disease; ARBs manufacturers spend millions to show the non-inferiority of their products compared to less expensive, generic ACE inhibitors; some athletes turn to growth hormone because it is difficult to detect; FDA Actions
-
